A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL
NCT05658562
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
46
Enrollment
INDUSTRY
Sponsor class
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
DRUG:
MT-2111
Sponsor
Tanabe Pharma Corporation